LEXIVA
LOE ApproachingNDAORALTABLET
Approved
Oct 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
5/8 — Partial
LEXIVA by GSK is [see microbiology (12. Approved for combination with other antiretroviral agents for the treatment of hiv-1 infection. First approved in 2003.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEXIVA (fosamprenavir) is an oral protease inhibitor approved in 2003 for HIV-1 treatment in combination with other antiretroviral agents. It works by inhibiting HIV protease, preventing viral replication in infected cells. Patients with HIV-1 infection use this drug as part of combination antiretroviral therapy.
$0.287MPart D
LOE ApproachingDeclining
Minimal commercial investment expected; team likely in maintenance mode with declining patient base and limited growth opportunities.
Mechanism of Action
[see Microbiology (12.4)] .
Clinical Trials (3)
Flexiva Pulse Registry
Started Nov 2021
201 enrolled
Urinary CalculiBenign Prostatic Hyperplasia
Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
Started Sep 2009
36 enrolled
HypertriglyceridemiaHIV Infection
KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks
Started May 2004
866 enrolled
HIV InfectionInfection, Human Immunodeficiency Virus
Worked on LEXIVA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.